The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities
Open accessAbstract
Current therapies for advanced hepatocellular carcinoma (HCC) are marginally effective and exacerbate underlying liver disease. The ability of immunotherapy to elicit nontoxic, systemic, long-lived anti-tumor activity makes it particularly well-suited for use in the setting of HCC. While therapeutic benefit has been achieved in early clinical trials, the efficacy of immune-based therapies is limited by several unique properties of HCC, most notably the inherently tolerogenic character of the liver in both healthy and diseased (chronically-infected or tumor-bearing) states. Therapeutic regimens that both counteract these immunosuppressive mechanisms and amplify tumor-specific immunity are expected to profoundly improve clinical outcomes for HCC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Bowen, D. G., Zen, M., Holz, L., Davis, T., McCaughan, G. W., & Bertolino, P. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21593 · Cited by 316
Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection
Das, A., Hoare, M., Davies, N., Lopes, A. R., Dunn, C., Kennedy, P. T. F., Alexander, G., Finney, H., Lawson, A., Plunkett, F. J., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072076 · Cited by 256
Dynamic Regulation of CD8 T Cell Tolerance Induction by Liver Sinusoidal Endothelial Cells
Schurich, A., Berg, M., Stabenow, D., Böttcher, J., Kern, M., Schild, H.-J., Kurts, C., Schuette, V., Burgdorf, S., Diehl, L., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902580 · Cited by 124
Cited by
The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
Khemlina, G., Ikeda, S., & Kurzrock, R. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0712-x · Cited by 464
Lu, Z., Zuo, B., Jing, R., Gao, X., Rao, Q., Liu, Z., Qi, H., Guo, H., & Yin, H. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.019 · Cited by 361
Wu, Q., Zhou, L., Lv, D., Zhu, X., & Tang, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0739-0 · Cited by 281
Recent advances in hepatocellular carcinoma therapy
Dutta, R., & Mahato, R. I. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.010 · Cited by 280
Rao, Q., Zuo, B., Lu, Z., Gao, X., You, A., Wu, C., Du, Z., & Yin, H. (2016) · Hepatology · doi:10.1002/hep.28549 · Cited by 246
Metadata
- Authors
- Pardee, A. D., & Butterfield, L. H.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2012-01
- Volume
- 1
- Issue
- 1
- Pages
- 48-55
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2008451487
- Cited by
- 160
- References
- 7
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. https://app.cochat.ai/papers/10.4161/onci.1.1.18344
- The paper
- Pardee, A. D., & Butterfield, L. H. (2012). Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. OncoImmunology. https://doi.org/10.4161/onci.1.1.18344
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.